CI seems beneficial in cases of OTOF mutation and Brown–Vialetto–Van Laere syndrome-related auditory neuropathies (OMIM#211530) [55,56], whereas patients will benefit less from a CI in cases of mutations affecting the auditory ganglion cells and auditory nerve [57,58]. The gene discussed is OTOF; the disease is auditory neuropathy.